Cann Pharmaceutical Australia (CPA) was launched in 2016 - and was the first Australian company to obtain a joint venture with a licensed medicinal cannabis company in Israel - Cann Pharmaceutical Ltd of Israel. CPA was founded with the goal of breaking into the international market for the provision of medicinal cannabis treatments to children with epilepsy.​

In Australia, CPA's management, board of directors and advisors consist of proven business, academic and medical leaders with extensive histories of achievement in the medicinal cannabis sector, clinical research, and biotechnology.

Collectively, the team's breadth of experience ranges from advanced agribusiness technology, biotechnology, healthcare and the pharmaceutical sectors, plus proven entrepreneurial and business development in Australia and Israel.


CPA's certifications include the issuing of a License for Medicinal Cannabis Cultivation and Production from the Office of Drugs Control (ODC) in 2017, and the issuing of a License for Medicinal Cannabis Manufacturing in 2019.